AMLX vs IONS vs BIIB vs MDGL vs ACAD vs JPM

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 3x trailing P/E (55. 0x forward), making it the more compelling value choice. Analysts rate Amylyx Pharmaceuticals, Inc. (AMLX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 3x versus Biogen Inc. at 22. 6x. On forward P/E, Biogen Inc. is actually cheaper at 13. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +339. 4%, compared to -49. 6% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: MDGL returned +38. 9% versus ACAD's -43. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 39β versus Amylyx Pharmaceuticals, Inc. 's 1. 47β — meaning AMLX is approximately 280% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Amylyx Pharmaceuticals, Inc. (AMLX) carries a lower debt/equity ratio of 2% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -40. 4% for Ionis Pharmaceuticals, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -40. 5% for IONS. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 7x forward P/E versus 55. 0x for ACADIA Pharmaceuticals Inc. — 41. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMLX: 76. 1% to $24. 50.

In this comparison, JPM (1.

9% yield) pays a dividend. AMLX, IONS, BIIB, MDGL, ACAD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), 1. 9% yield, +454. 4% 10Y return). Both have compounded well over 10 years (JPM: +454. 4%, AMLX: -17. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AMLX (Healthcare) and IONS (Healthcare) and BIIB (Healthcare) and MDGL (Healthcare) and ACAD (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AMLX is a small-cap quality compounder stock; IONS is a mid-cap high-growth stock; BIIB is a mid-cap quality compounder stock; MDGL is a mid-cap high-growth stock; ACAD is a small-cap deep-value stock; JPM is a large-cap deep-value stock. JPM pays a dividend while AMLX, IONS, BIIB, MDGL, ACAD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.